NCT00626860已完成1 期
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- To assess the toxicity, cellular and humoral immunity and tumor response in patient with melanoma receiving the DC/tumor fusion vaccine
研究概览
简要总结
This study aims to determine if the vacccine can be used safely in patients with advanced melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of producing immune responses against your own cancer.
详细描述
To assess the toxicity associated with vaccination of melanoma patients with dendritic cell (DC)/tumor fusions. To determine if cellular and humoral immunity can be induced by serial vaccination with DC/tumor fusions cells. To determine if vaccination DC/tumor fusions results in a tumor response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with confirmed diagnoses of disseminated melanoma, with measurable and clearly progressive metastatic involevment
- •Patients must be at least 18 years old
- •Patients must have ECOG performance status 0-1 with greater than 9 week life expectancy
- •Those patients with the following accessible tumor will be eligible: soft tissue, bone marrow or visceral lesions; Skin or superficial soft tissue, or lymph nodes amenable to resection under local anesthesia; Patients who require surgical procedures that are not considered significantly invasive but may require general anesthesia, such as thorascopic biopsy, laparascopic biopsy or mediastinal node biopsy may potentially be eligible; Malignant ascites or pleural effusion; Patients requiring major surgical intervention will be considered ineligible. Patients scheduled to undergo tumor resection for independent diagnostic or therapeutic indications may have tumor collected for the purposes of this study.
- •Labs: WBC >_ 2.0 x 10x3/uL, Bilirubin <_2.0 mg/dL, Creatine <_ 2.0mg/dL
- •Women of childbearing age must have a negative pregnancy test and adequate contraception method(s) must be documented
- •All patients must be informed of the investigational nature of this study and must give written informed consent in accordance with institutional and federal guidelines
排除标准
- •Patients must not have received other immunotherapy treatment in the past four weeks prior to study entry
- •Patients must not have received chemotherapy for three weeks prior to the first vaccination
- •Patients must be without evidence of active CNS disease
- •Patients must not have clinically significant autoimmune disease
- •Patients must be HIV negative
- •Patients must not have serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure
- •Patients requiring corticosteroids for either melanoma related or co-morbid illness
结局指标
主要结局
To assess the toxicity, cellular and humoral immunity and tumor response in patient with melanoma receiving the DC/tumor fusion vaccine
时间窗: screening/baseline, treatment period and follow-up
次要结局
未报告次要终点
研究者
David Avigan
Professor of Medicine
Beth Israel Deaconess Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant MesotheliomaMalignant (Pleural) MesotheliomaNCT01241682Erasmus Medical Center10
已完成
1 期
Vaccination of Patients With Stage IV Melanoma With Dendritic CellsNeoplasm MetastasisMelanomaNCT00125749Baylor Research Institute30
已完成
1 期
The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple MyelomaMultiple MyelomaNCT00459069Beth Israel Deaconess Medical Center18
终止
1 期
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12Breast CancerNCT00622401Beth Israel Deaconess Medical Center8
已完成
1 期
Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic CancerPancreatic CancerNCT00547144George Albert Fisher2